Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Update

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 4,150,000 shares, an increase of 10.4% from the May 31st total of 3,760,000 shares. Currently, 11.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 341,900 shares, the days-to-cover ratio is currently 12.1 days.

Amphastar Pharmaceuticals Stock Down 2.4 %

NASDAQ:AMPH opened at $37.58 on Wednesday. Amphastar Pharmaceuticals has a twelve month low of $37.30 and a twelve month high of $67.66. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 13.00, a price-to-earnings-growth ratio of 0.82 and a beta of 0.80. The stock has a fifty day simple moving average of $41.51 and a 200-day simple moving average of $47.48. The company has a current ratio of 2.18, a quick ratio of 1.72 and a debt-to-equity ratio of 0.88.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.20. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. The business had revenue of $171.84 million during the quarter, compared to the consensus estimate of $171.13 million. Analysts anticipate that Amphastar Pharmaceuticals will post 3.6 EPS for the current year.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total transaction of $124,200.00. Following the completion of the sale, the director now directly owns 78,409 shares of the company’s stock, valued at approximately $3,246,132.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the transaction, the director now directly owns 78,409 shares of the company’s stock, valued at $3,246,132.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO William J. Peters sold 3,596 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $3,851,635.79. The disclosure for this sale can be found here. Insiders sold a total of 7,596 shares of company stock valued at $313,544 in the last three months. 27.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Amphastar Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. McGlone Suttner Wealth Management Inc. bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth $28,000. Principal Securities Inc. bought a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $34,000. YHB Investment Advisors Inc. bought a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at about $27,000. Quadrant Capital Group LLC raised its holdings in shares of Amphastar Pharmaceuticals by 27.8% in the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after acquiring an additional 223 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Amphastar Pharmaceuticals by 115.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock valued at $150,000 after acquiring an additional 1,300 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AMPH. Piper Sandler restated an “overweight” rating and issued a $71.00 price target on shares of Amphastar Pharmaceuticals in a research report on Thursday, June 27th. JPMorgan Chase & Co. began coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price target for the company. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, May 22nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.